vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
Smith Douglas Homes Corp. is the larger business by last-quarter revenue ($260.4M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 1.4%, a 9.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -9.4%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $8.7M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 17.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
ANIP vs SDHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $260.4M |
| Net Profit | $27.5M | $3.5M |
| Gross Margin | — | 19.9% |
| Operating Margin | 14.1% | 6.5% |
| Net Margin | 11.1% | 1.4% |
| Revenue YoY | 29.6% | -9.4% |
| Net Profit YoY | 367.5% | -14.3% |
| EPS (diluted) | $1.14 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $260.4M | ||
| Q3 25 | $227.8M | $262.0M | ||
| Q2 25 | $211.4M | $223.9M | ||
| Q1 25 | $197.1M | $224.7M | ||
| Q4 24 | $190.6M | $287.5M | ||
| Q3 24 | $148.3M | $277.8M | ||
| Q2 24 | $138.0M | $220.9M | ||
| Q1 24 | $137.4M | $189.2M |
| Q4 25 | $27.5M | $3.5M | ||
| Q3 25 | $26.6M | $2.1M | ||
| Q2 25 | $8.5M | $2.4M | ||
| Q1 25 | $15.7M | $2.7M | ||
| Q4 24 | $-10.3M | $4.1M | ||
| Q3 24 | $-24.2M | $5.3M | ||
| Q2 24 | $-2.3M | $3.6M | ||
| Q1 24 | $18.2M | $3.0M |
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | — | 23.2% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 25.5% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 26.7% | ||
| Q1 24 | — | 26.1% |
| Q4 25 | 14.1% | 6.5% | ||
| Q3 25 | 15.9% | 6.6% | ||
| Q2 25 | 6.6% | 7.7% | ||
| Q1 25 | 13.3% | 8.7% | ||
| Q4 24 | -2.3% | 10.4% | ||
| Q3 24 | -13.8% | 14.2% | ||
| Q2 24 | 3.7% | 11.7% | ||
| Q1 24 | 14.8% | 11.3% |
| Q4 25 | 11.1% | 1.4% | ||
| Q3 25 | 11.7% | 0.8% | ||
| Q2 25 | 4.0% | 1.1% | ||
| Q1 25 | 8.0% | 1.2% | ||
| Q4 24 | -5.4% | 1.4% | ||
| Q3 24 | -16.3% | 1.9% | ||
| Q2 24 | -1.7% | 1.7% | ||
| Q1 24 | 13.2% | 1.6% |
| Q4 25 | $1.14 | $0.39 | ||
| Q3 25 | $1.13 | $0.24 | ||
| Q2 25 | $0.36 | $0.26 | ||
| Q1 25 | $0.69 | $0.30 | ||
| Q4 24 | $-0.45 | $0.50 | ||
| Q3 24 | $-1.27 | $0.58 | ||
| Q2 24 | $-0.14 | $0.40 | ||
| Q1 24 | $0.82 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $12.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $86.7M |
| Total Assets | $1.4B | $557.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $12.7M | ||
| Q3 25 | $262.6M | $14.8M | ||
| Q2 25 | $217.8M | $16.8M | ||
| Q1 25 | $149.8M | $12.7M | ||
| Q4 24 | $144.9M | $22.4M | ||
| Q3 24 | $145.0M | $23.7M | ||
| Q2 24 | $240.1M | $17.3M | ||
| Q1 24 | $228.6M | $32.8M |
| Q4 25 | $540.7M | $86.7M | ||
| Q3 25 | $505.8M | $82.2M | ||
| Q2 25 | $436.8M | $80.0M | ||
| Q1 25 | $418.6M | $76.9M | ||
| Q4 24 | $403.7M | $73.6M | ||
| Q3 24 | $405.9M | $68.4M | ||
| Q2 24 | $455.8M | $62.1M | ||
| Q1 24 | $452.0M | $59.7M |
| Q4 25 | $1.4B | $557.6M | ||
| Q3 25 | $1.4B | $571.6M | ||
| Q2 25 | $1.3B | $570.2M | ||
| Q1 25 | $1.3B | $513.9M | ||
| Q4 24 | $1.3B | $475.9M | ||
| Q3 24 | $1.3B | $460.1M | ||
| Q2 24 | $920.8M | $429.3M | ||
| Q1 24 | $914.5M | $401.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $9.8M |
| Free Cash FlowOCF − Capex | $29.1M | $8.7M |
| FCF MarginFCF / Revenue | 11.8% | 3.4% |
| Capex IntensityCapex / Revenue | 0.5% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $9.8M | ||
| Q3 25 | $44.1M | $22.8M | ||
| Q2 25 | $75.8M | $-28.9M | ||
| Q1 25 | $35.0M | $-34.9M | ||
| Q4 24 | $15.9M | $5.5M | ||
| Q3 24 | $12.5M | $22.9M | ||
| Q2 24 | $17.4M | $39.0K | ||
| Q1 24 | $18.3M | $-9.3M |
| Q4 25 | $29.1M | $8.7M | ||
| Q3 25 | $38.0M | $21.4M | ||
| Q2 25 | $71.8M | $-31.1M | ||
| Q1 25 | $32.5M | $-35.9M | ||
| Q4 24 | $13.5M | $4.8M | ||
| Q3 24 | $7.7M | $22.3M | ||
| Q2 24 | $13.0M | $-2.1M | ||
| Q1 24 | $13.7M | $-9.7M |
| Q4 25 | 11.8% | 3.4% | ||
| Q3 25 | 16.7% | 8.2% | ||
| Q2 25 | 34.0% | -13.9% | ||
| Q1 25 | 16.5% | -16.0% | ||
| Q4 24 | 7.1% | 1.7% | ||
| Q3 24 | 5.2% | 8.0% | ||
| Q2 24 | 9.4% | -1.0% | ||
| Q1 24 | 10.0% | -5.1% |
| Q4 25 | 0.5% | 0.4% | ||
| Q3 25 | 2.7% | 0.5% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 1.3% | 0.5% | ||
| Q4 24 | 1.3% | 0.2% | ||
| Q3 24 | 3.2% | 0.2% | ||
| Q2 24 | 3.2% | 1.0% | ||
| Q1 24 | 3.3% | 0.2% |
| Q4 25 | 1.10× | 2.77× | ||
| Q3 25 | 1.66× | 10.70× | ||
| Q2 25 | 8.87× | -12.24× | ||
| Q1 25 | 2.23× | -13.01× | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | — | 4.28× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | 1.00× | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
